No worries Mirri. Agreed - the split would be helpful.
The common figure I see in literature is ~30% of CRT patients are non-responders, a notable portion of which is related to ineffective lead placement. Using the top-line figures in the prospectus, that's 29,100 patients or an addressable market of ~$1.0B US in the States alone. A huge opportunity that is out-of-scope for the time-being.
General Investor Information EBR Systems, page-177
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.000(0.00%) |
Mkt cap ! $382.2M | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.10 | $1.05 | $563.8K | 525.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13673 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 1387 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| EBR (ASX) Chart |